First Interchangeability Designation Opens Doors For Biosimilars
Pharmacy Substitution For Semglee Now Possible Without Prescriber Intervention
An FDA decision to award Viatris a landmark interchangeability designation for its Semglee insulin glargine biosimilar has been welcomed by industry representatives.
You may also be interested in...
Biopharma is entering a new period of intense competition from new sources, requiring a change in approach to portfolio strategy and lifecycle management.
Amgen’s 2021 Biosimilars Trends Report predicts several imminent advancements in the biosimilars space, especially with the expected US launches of biosimilars to Humira in 2023. According to Amgen, the marketplace is poised to see further growth.
Viatris has provided an update on its biosimilar pipeline, covering assets including insulin glargine, insulin aspart, aflibercept and bevacizumab, as part of its second quarter strategic update.